Drugs / TQB3303
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04275050 | Apr 2020 → Apr 2021 | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04275050 ↗ |
| Action | Inhibit | “inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6)” NCT04275050 ↗ |
| Modality | Small molecule | “small molecule oral drug” NCT04275050 ↗ |
| Route | Oral | “small molecule oral drug” NCT04275050 ↗ |
| Target | CDK4 | “inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6)” NCT04275050 ↗ |